TC BioPharm Expands ACHIEVE AML Trial with New Site at Guys and St. Thomas Hospital
Key Insights
TC BioPharm has opened a new clinical trial site at Guys and St. Thomas Hospital (search) in London to accelerate enrollment in the ACHIEVE study.
The ACHIEVE trial is a Phase II study evaluating TCB008, an allogeneic gamma-delta T cell therapy, for acute myeloid leukemia (AML (search)) and MDS/AML (search) patients.
Dr. Hugues de Lavallade, a hematologist with expertise in myeloid disorders, will serve as the Principal Investigator at the new site.
TC BioPharm (Holdings) PLC has announced the opening of a new clinical trial site at Guys and St. Thomas Hospital (search) in London for the ACHIEVE UK trial. This Phase II study is evaluating the efficacy of TCB008, an allogeneic gamma-delta T cell therapy, in patients with acute myeloid leukemia (AML (search)) or MDS/AML (search) who have relapsed or refractory disease. The addition of this site aims to expedite the trial's progression and data readout.
New Site and Principal Investigator
Guys and St. Thomas Hospital (search), a leading London-based institution, brings extensive experience in cell therapy and oncology trials to the ACHIEVE study. Dr. Hugues de Lavallade, a consultant hematologist specializing in myeloid disorders, will serve as the Principal Investigator. His expertise in treating AML (search) patients with measurable residual disease is expected to significantly contribute to the trial's success.
ACHIEVE Trial Design and Objectives
The ACHIEVE UK clinical trial is an open-label, Phase II study designed to assess the effectiveness of TCB008 in AML (search) and MDS/AML (search) patients with refractory or relapsed disease. TCB008 is TC BioPharm's allogeneic gamma-delta T cell therapy, which harnesses the unique properties of gamma-delta T cells to target and eliminate cancer cells while sparing healthy tissue. The trial aims to provide an alternative treatment option for seriously ill AML patients.
Progress and Anticipated Data
According to Alison Bracchi, Executive Vice President of Clinical at TC BioPharm, the ACHIEVE clinical trial has shown positive progress since the dose increase earlier this year, with strong enrollment and remains on schedule for data in the first half of 2025. The company is partnering with several centers of excellence to advance the trial and offer new hope to AML (search) patients.
About TCB008
TCB008 is based on gamma-delta T cells, which are naturally occurring immune cells that can differentiate between healthy and diseased tissue. TC BioPharm is focused on developing these therapies for cancer treatment, with human efficacy data already demonstrated in acute myeloid leukemia.